Skip to the content
Altai Oncology - Softwarelogo darklogo light
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us
Altai Oncology - Softwarelogo darklogo light
Renal Cell Carcinoma

New Reference: Nivolumab and Cabozantinib for Advanced RCC

Ulas D. Bayraktar, MD
2022-09-20
Nervous System Tumor Thyroid Cancer

New Indication: Dabrafenib and Trametinib in bRAV V600E Mutant Anaplastic Thyroid Cancer

Ulas D. Bayraktar, MD
2022-09-20
GastroEsophageal Cancer

New Protocol: Perioperative FLOT with Trastuzumab and Pertuzumab for her2-Positive Gastroesophageal Cancer

Ulas D. Bayraktar, MD
2022-07-16
Acute myeloid leukemia

New Protocol: Venetoclax with 3 + 7 Chemotherapy for AML

Ulas D. Bayraktar, MD
2022-07-16
Colorectal Cancer

New Indication: Pembrolizumab for MSI-High Colorectal Cancer

Ulas D. Bayraktar, MD
2022-07-16
Cervical Cancer

New Reference: Cemiplimab for Cervical Cancer

Ulas D. Bayraktar, MD
2022-05-20
Prostate Cancer

New Indication: Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

Ulas D. Bayraktar, MD
2022-05-20
Prostate Cancer

New Protocol: Abiraterone with DOCEtaxel in CRPC

Ulas D. Bayraktar, MD
2022-05-20
Acute myeloid leukemia

New Protocol: Ivosidenib and Azacitidine in IDH1-Mutated AML

Ulas D. Bayraktar, MD
2022-05-20
Melanoma

New Indication: Adjuvant Pembrolizumab for Melanoma

Ulas D. Bayraktar, MD
2022-05-20

Posts pagination

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
  • Library
  • F.A.Q.
  • Contact Us

Privacy Policy

Altai, Inc (USA)

30 N Gould St, Ste 6801

Sheridan, WY, 82801, USA

Phone: +1 (978) 393 0042

Altay Tıp Sağlık Yazılım AŞ (Türkiye)

Mutlukent Mah Manuk Bey Sk No: 4

Çankaya, Ankara, 06800, Türkiye

Phone: +90 (312) 911 5735

Our Terms & Privacy Policy

Copyright - 2024 - Altai Inc - All rights reserved

Back to top Drag
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us

jghghjghjghhgj